APA (7th ed.) Citation

Fedyanin, M. Y., Snegovoy, A. V., Breder, V. V., Linkova, Y. N., Zinkina-Orikhan, A. V., Setkina, S. B., . . . Kravtsova, N. A. (2023). Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria). Bezopasnostʹ i risk farmakoterapii (Online), 11(2), 215-230. https://doi.org/10.30895/2312-7821-2023-11-2-360

Chicago Style (17th ed.) Citation

Fedyanin, M. Yu, A. V. Snegovoy, V. V. Breder, Yu. N. Linkova, A. V. Zinkina-Orikhan, S. B. Setkina, S. N. Fogt, V. S. Chistiakov, and N. A. Kravtsova. "Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)." Bezopasnostʹ I Risk Farmakoterapii (Online) 11, no. 2 (2023): 215-230. https://doi.org/10.30895/2312-7821-2023-11-2-360.

MLA (9th ed.) Citation

Fedyanin, M. Yu, et al. "Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)." Bezopasnostʹ I Risk Farmakoterapii (Online), vol. 11, no. 2, 2023, pp. 215-230, https://doi.org/10.30895/2312-7821-2023-11-2-360.